Treatment of premenstrual dysphoric disorder

Current effective version

PDF iconAdopted guideline

Reference numberCHMP/607022/2009
Effective from01/02/2012
KeywordsPremenstrual dysphoric disorder (PMDD)
DescriptionThis document provides guidance on the evaluation of medicinal products in the treatment of premenstrual dysphoric disorder. It addresses the identification of the target population including special populations (adolescents), study duration as well as efficacy and safety endpoints.

Document history

First version

Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

PDF iconConcept paper

In operation: 01/02/2012–present

Published: 05/08/2011

Published: 24/05/2010

Published: 19/02/2009

Related content

How useful was this page?

Add your rating